Literature DB >> 31034819

Circulating Lymphangioleiomyomatosis Tumor Cells With Loss of Heterozygosity in the TSC2 Gene Show Increased Aldehyde Dehydrogenase Activity.

Gustavo Pacheco-Rodríguez1, Wendy K Steagall1, Leigh Samsel2, Pradeep K Dagur2, J Philip McCoy2, Ilker Tunc3, Mehdi Pirooznia3, Ji-An Wang4, Thomas N Darling4, Joel Moss5.   

Abstract

BACKGROUND: Lymphangioleiomyomatosis (LAM) is a destructive metastasizing neoplasm of the lung characterized by proliferation of LAM cells in specialized lung nodules. LAM cells are characterized by expression of the prometastatic and cancer-initiating hyaluronan receptor CD44v6, and loss of heterozygosity (LOH) of TSC1 and TSC2. The circulating neoplastic LAM cells are thought to be involved in metastasis. Because LAM cells display properties of neoplastic, metastatic, and stem cell-like cancer cells, we hypothesized that elevated aldehyde dehydrogenase (ALDH) activity, characteristic of cancer and stem cells, is a property of LAM cells.
METHODS: We performed an in silico search of ALDH genes in microdissected LAM lung nodules. To identify circulating LAM cells, we osmotically removed red blood cells from whole blood to obtain peripheral blood mononuclear cells, which were then sorted by fluorescence-activated cell sorting based on their level of ALDH activity.
RESULTS: Microdissected LAM lung nodules possess a distinctive ALDH gene profile. The cell subpopulation with high ALDH activity, isolated from circulating cells, possessed TSC2 LOH in 8 of 14 patients with LAM. Approximately 60% of the circulating cells with high ALDH activity expressed CD44v6. Cells with TSC2 LOH from patients with LAM and LAM/TSC exhibited different properties in different body locations, but all cell types showed high ALDH activity.
CONCLUSIONS: This new procedure allows for isolation of circulating LAM cells from cultured cells, blood, and chylous effusions and shows that circulating LAM cells are heterogeneous with neoplastic, metastatic, and cancer-stem cell-like properties.
Copyright © 2019. Published by Elsevier Inc.

Entities:  

Keywords:  biomarkers; circulating tumor cells; loss of heterozygosity; lymphangioleiomyomatosis; tuberous sclerosis complex

Mesh:

Substances:

Year:  2019        PMID: 31034819      PMCID: PMC6859254          DOI: 10.1016/j.chest.2019.03.040

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  39 in total

Review 1.  mTOR signaling in growth control and disease.

Authors:  Mathieu Laplante; David M Sabatini
Journal:  Cell       Date:  2012-04-13       Impact factor: 41.582

2.  Genetic heterogeneity of circulating cells from patients with lymphangioleiomyomatosis with and without lung transplantation.

Authors:  Wendy K Steagall; Li Zhang; Xiong Cai; Gustavo Pacheco-Rodriguez; Joel Moss
Journal:  Am J Respir Crit Care Med       Date:  2015-04-01       Impact factor: 21.405

3.  CD44v6 is a marker of constitutive and reprogrammed cancer stem cells driving colon cancer metastasis.

Authors:  Matilde Todaro; Miriam Gaggianesi; Veronica Catalano; Antonina Benfante; Flora Iovino; Mauro Biffoni; Tiziana Apuzzo; Isabella Sperduti; Silvia Volpe; Gianfranco Cocorullo; Gaspare Gulotta; Francesco Dieli; Ruggero De Maria; Giorgio Stassi
Journal:  Cell Stem Cell       Date:  2014-03-06       Impact factor: 24.633

4.  Inhibition of aldehyde dehydrogenase and retinoid signaling induces the expansion of human hematopoietic stem cells.

Authors:  John P Chute; Garrett G Muramoto; John Whitesides; Michael Colvin; Rachid Safi; Nelson J Chao; Donald P McDonnell
Journal:  Proc Natl Acad Sci U S A       Date:  2006-07-20       Impact factor: 11.205

5.  Aldehyde dehydrogenase activity in leukemic blasts defines a subgroup of acute myeloid leukemia with adverse prognosis and superior NOD/SCID engrafting potential.

Authors:  A M S Cheung; T S K Wan; J C K Leung; L Y Y Chan; H Huang; Y L Kwong; R Liang; A Y H Leung
Journal:  Leukemia       Date:  2007-05-03       Impact factor: 11.528

6.  Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer.

Authors:  Feng Jiang; Qi Qiu; Abha Khanna; Nevins W Todd; Janaki Deepak; Lingxiao Xing; Huijun Wang; Zhenqiu Liu; Yun Su; Sanford A Stass; Ruth L Katz
Journal:  Mol Cancer Res       Date:  2009-03-10       Impact factor: 5.852

7.  Osteoprotegerin contributes to the metastatic potential of cells with a dysfunctional TSC2 tumor-suppressor gene.

Authors:  Wendy K Steagall; Gustavo Pacheco-Rodriguez; Connie G Glasgow; Yoshihiko Ikeda; Jing-Ping Lin; Gang Zheng; Joel Moss
Journal:  Am J Pathol       Date:  2013-07-16       Impact factor: 4.307

8.  TSC2 loss in lymphangioleiomyomatosis cells correlated with expression of CD44v6, a molecular determinant of metastasis.

Authors:  Gustavo Pacheco-Rodriguez; Wendy K Steagall; Denise M Crooks; Linda A Stevens; Hiroshi Hashimoto; Shaowei Li; Ji-an Wang; Thomas N Darling; Joel Moss
Journal:  Cancer Res       Date:  2007-11-01       Impact factor: 12.701

Review 9.  Lymphangioleiomyomatosis.

Authors:  Simon R Johnson; Angelo M Taveira-DaSilva; Joel Moss
Journal:  Clin Chest Med       Date:  2016-09       Impact factor: 2.878

Review 10.  The neural crest lineage as a driver of disease heterogeneity in Tuberous Sclerosis Complex and Lymphangioleiomyomatosis.

Authors:  Sean P Delaney; Lisa M Julian; William L Stanford
Journal:  Front Cell Dev Biol       Date:  2014-11-25
View more
  5 in total

1.  Pulmonary Langerhans Cell Histiocytosis and Lymphangioleiomyomatosis Have Circulating Cells With Loss of Heterozygosity of the TSC2 Gene.

Authors:  Davide Elia; Olga Torre; Chiara Vasco; Jens Geginat; Sergio Abrignani; Elisabetta Bulgheroni; Elena Carelli; Roberto Cassandro; Gustavo Pacheco-Rodriguez; Wendy K Steagall; Joel Moss; Sergio Harari
Journal:  Chest       Date:  2022-02-26       Impact factor: 10.262

2.  LAM Cells as Potential Drivers of Senescence in Lymphangioleiomyomatosis Microenvironment.

Authors:  Clara Bernardelli; Silvia Ancona; Melania Lazzari; Antonella Lettieri; Piera Selvaggio; Valentina Massa; Cristina Gervasini; Fabiano Di Marco; Raffaella Chiaramonte; Elena Lesma
Journal:  Int J Mol Sci       Date:  2022-06-24       Impact factor: 6.208

3.  Evidence for shared genetic risk factors between lymphangioleiomyomatosis and pulmonary function.

Authors:  Xavier Farré; Roderic Espín; Alexandra Baiges; Eline Blommaert; Wonji Kim; Krinio Giannikou; Carmen Herranz; Antonio Román; Berta Sáez; Álvaro Casanova; Julio Ancochea; Claudia Valenzuela; Piedad Ussetti; Rosalía Laporta; José A Rodríguez-Portal; Coline H M van Moorsel; Joanne J van der Vis; Marian J R Quanjel; Mireia Tena-Garitaonaindia; Fermín Sánchez de Medina; Francesca Mateo; María Molina-Molina; Sungho Won; David J Kwiatkowski; Rafael de Cid; Miquel Angel Pujana
Journal:  ERJ Open Res       Date:  2022-01-24

4.  Histamine signaling and metabolism identify potential biomarkers and therapies for lymphangioleiomyomatosis.

Authors:  Carmen Herranz; Francesca Mateo; Alexandra Baiges; Gorka Ruiz de Garibay; Alexandra Junza; Simon R Johnson; Suzanne Miller; Nadia García; Jordi Capellades; Antonio Gómez; August Vidal; Luis Palomero; Roderic Espín; Ana I Extremera; Eline Blommaert; Eva Revilla-López; Berta Saez; Susana Gómez-Ollés; Julio Ancochea; Claudia Valenzuela; Tamara Alonso; Piedad Ussetti; Rosalía Laporta; Antoni Xaubet; José A Rodríguez-Portal; Ana Montes-Worboys; Carlos Machahua; Jaume Bordas; Javier A Menendez; Josep M Cruzado; Roser Guiteras; Christophe Bontoux; Concettina La Motta; Aleix Noguera-Castells; Mario Mancino; Enrique Lastra; Raúl Rigo-Bonnin; Jose C Perales; Francesc Viñals; Alvaro Lahiguera; Xiaohu Zhang; Daniel Cuadras; Coline H M van Moorsel; Joanne J van der Vis; Marian J R Quanjel; Harilaos Filippakis; Razq Hakem; Chiara Gorrini; Marc Ferrer; Aslihan Ugun-Klusek; Ellen Billett; Elżbieta Radzikowska; Álvaro Casanova; María Molina-Molina; Antonio Roman; Oscar Yanes; Miquel A Pujana
Journal:  EMBO Mol Med       Date:  2021-08-11       Impact factor: 12.137

5.  Heterogeneity and Cancer-Related Features in Lymphangioleiomyomatosis Cells and Tissue.

Authors:  Roderic Espín; Alexandra Baiges; Eline Blommaert; Carmen Herranz; Antonio Roman; Berta Saez; Julio Ancochea; Claudia Valenzuela; Piedad Ussetti; Rosalía Laporta; José A Rodríguez-Portal; Coline H M van Moorsel; Joanne J van der Vis; Marian J R Quanjel; Anna Villar-Piqué; Daniela Diaz-Lucena; Franc Llorens; Álvaro Casanova; María Molina-Molina; Mireya Plass; Francesca Mateo; Joel Moss; Miquel Angel Pujana
Journal:  Mol Cancer Res       Date:  2021-07-26       Impact factor: 6.333

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.